Clinical Trials Logo

Clinical Trial Summary

This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the samples will be taken during routinary clinical practice. The aim of this study is to analyze the immunobiology of Acute Myeloid Leukemia (AML) relapses after allogeneic HSCT for the generation of guidelines and personalized therapeutic pathways.

Clinical Trial Description

Background: The identification of leukemic relapses characterized by the "Human Leukocyte Antigens loss" event or by changes in the expression levels of genes involved in antigen presentation and lymphocyte co-stimulation demonstrate how a complete characterization of disease recurrence is necessary to ensure the patient a treatment that is as personalized and targeted as possible, avoiding the choice of sub-optimal or, sometimes, harmful therapies. Unfortunately, the identification of the post-transplant relapse mechanism is now far from being part of an established clinical routine, mainly due to the lack of quick and easy-to-access diagnostic tools and multicentre studies demonstrating the efficacy of a type of personalized therapeutic approach. The main objective of the study is to favor, exploiting the consolidated collaboration between the Italian transplant centers belonging to the Italian Group of Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapies (GITMO), the implementation in clinical practice of an in-depth biological study of relapses of leukemia in order to allow an increasingly targeted and effective planning of the therapeutic strategies to be implemented, ensuring better patient survival. The study is divided into two parts: - data collection, from clinical standard practice, of patients with relapse of the disease which will allow to standardize the therapeutic management process and will allow us to promote innovative clinical studies on acute myeloid leukemia post allogeneic HSCT, with the ultimate aim of improving the survival of these patients; - biological substudy that will allow to define the role of the tumor microenvironment in promoting or counteracting the phenomenon of relapse by identifying its specific alterations in the various forms of disease relapse. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05124288
Study type Observational
Source IRCCS San Raffaele
Contact Fabio Ciceri, MD
Phone +39 02-2643-3093
Email [email protected]
Status Not yet recruiting
Start date December 20, 2021
Completion date June 20, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02204085 - A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT04898894 - Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT05105152 - PLAT-08: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Phase 1
Recruiting NCT04402541 - Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT03690154 - A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Phase 1
Recruiting NCT03957915 - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia Early Phase 1
Completed NCT04321161 - Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment Early Phase 1
Recruiting NCT04678336 - CD123 Redirected T Cells for AML in Pediatric Subjects Phase 1
Not yet recruiting NCT04716452 - Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT03053206 - A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT03766126 - Lentivirally Redirected CD123 Autologous T Cells in AML Phase 1
Terminated NCT02353143 - Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT02438761 - PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04914845 - KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT02768792 - High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Phase 2
Not yet recruiting NCT03116477 - Study Investigating the Efficacy of the Addition of Crenolanib to Chemotherapy vs Chemotherapy Alone in Patients With R/R FLT3 Mutated AML Phase 3